Multisystemic inflammatory syndrome related to COVID-19, with latent tuberculosis in bone marrow, and satisfactory response to tocilizumab, in a 7-year-old boy
Z. Morel,
R. Suarez,
E. Avalos,
S. Velázquez,
F. Martínez,
V. Lezcano,
N. Astigarraga,
C. Ghezzi,
S. Brizuela,
G. Samudio
Affiliations
Z. Morel
Pediatric Rheumatology, Pediatric Department, Central Hospital of the Social Welfare Institute, Asunción
R. Suarez
Pediatrics, Pediatric Department, Central Hospital of the Social Welfare Institute, Asunción
E. Avalos
Pediatrics, Pediatric Department, Central Hospital of the Social Welfare Institute, Asunción
S. Velázquez
Pediatric Intensive Care, Pediatric Department, Central Hospital of the Social Welfare Institute, Asunción
F. Martínez
Pediatric Infectology, Pediatric Department, Central Hospital of the Social Welfare Institute, Asunción
V. Lezcano
Pediatric Infectology, Pediatric Department, Central Hospital of the Social Welfare Institute, Asunción, Paraguay
N. Astigarraga
Pediatric Cardiology, Pediatric Department, Central Hospital of the Social Welfare Institute, Asunción
C. Ghezzi
Pediatrics, Pediatric Department, Central Hospital of the Social Welfare Institute, Asunción
S. Brizuela
Pediatric Hematology, Pediatric Department, Central Hospital of the Social Welfare Institute, Asunción
G. Samudio
Pediatric Infectology, Pediatric Department, Central Hospital of the Social Welfare Institute, Asunción
Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS) or multisystem inflammatory syndrome in children (MIS-C) is a new acute-onset systemic inflammatory disease, which mainly affects children. Latent tuberculosis infection (LTBI) is characterized by the presence of immune sensitization to Mycobacterium tuberculosis (MTB) in the absence of any clinical or radiological evidence of active disease. We present a child with MIS-C related to COVID-19, with latent TB in the bone marrow, and satisfactory response to tocilizumab. It is important to pay attention in the investigation of TB cases in countries with a high prevalence of tuberculosis, especially when opting for immunusuppression.
